Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Cericlamine

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Cericlamine
Clinical data
Other namesJO-1017
Routes of
administration
Oral[1]
ATC code
  • None
Pharmacokinetic data
Eliminationhalf-life8 hours[1]
Identifiers
  • 3-(3,4-Dichlorophenyl)-2-(dimethylamino)-2-methylpropan-1-ol
CAS Number
PubChemCID
ChemSpider
UNII
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC12H17Cl2NO
Molar mass262.17 g·mol−1
3D model (JSmol)
  • CC(CC1=CC(=C(C=C1)Cl)Cl)(CO)N(C)C
  • InChI=1S/C12H17Cl2NO/c1-12(8-16,15(2)3)7-9-4-5-10(13)11(14)6-9/h4-6,16H,7-8H2,1-3H3
  • Key:FWYRGHMKHZXXQX-UHFFFAOYSA-N

Cericlamine (INN; developmental codeJO-1017) is a potent and moderatelyselective serotonin reuptake inhibitor (SSRI) of theamphetamine family (specifically, aderivative ofphentermine, and closely related tochlorphentermine, a highly selectiveserotonin releasing agent) that was investigated as anantidepressant for the treatment ofdepression,anxiety disorders, andanorexia nervosa by Jouveinal but did not complete development and was never marketed.[1][2][3][4] It reachedphase IIIclinical trials in 1996 before development was discontinued in 1999.[5]

According to Czech scientists, cericlamine is claimed to be part of a highly advanced “fifth generation” of antidepressants as was venlafaxine.[6]

The daily dosage was reported to be 300mg.[1]

See also

[edit]

References

[edit]
  1. ^abcdDarcourt G, Tessera M, Lesaunier R, Engrand P, Scherrer B, Dreyfus J, Bogaievsky Y (1992). "A Multicentre Double-Blind, Placebo-Controlled Dose-Finding Study with Cericlamine in Major Depression".Clinical Neuropharmacology.15: 176B.doi:10.1097/00002826-199202001-00339.ISSN 0362-5664.S2CID 57983762.
  2. ^Crow S, Brown E (March 2003). "Investigational drugs for eating disorders".Expert Opinion on Investigational Drugs.12 (3):491–9.doi:10.1517/13543784.12.3.491.PMID 12605570.S2CID 25463729.
  3. ^Patel RM (3 January 2000).Stereoselective Biocatalysis. CRC Press. pp. 48–.ISBN 978-0-8247-8282-5.
  4. ^Tang LC, Tang SJ (6 December 2012).Neurochemistry in Clinical Application. Springer Science & Business Media. pp. 81–.ISBN 978-1-4615-1857-0.
  5. ^"Cericlamine".AdisInsight. Springer Nature Switzerland AG. Retrieved13 January 2016.
  6. ^Svestka, J. (1994). "Antidepressives of the 3rd, 4th and 5th generation".Ceskoslovenska Psychiatrie.90 (1):3–19.PMID 8174184.
DATTooltip Dopamine transporter
(DRIsTooltip Dopamine reuptake inhibitors)
NETTooltip Norepinephrine transporter
(NRIsTooltip Norepinephrine reuptake inhibitors)
SERTTooltip Serotonin transporter
(SRIsTooltip Serotonin reuptake inhibitors)
VMATsTooltip Vesicular monoamine transporters
Others
Phenethylamines
Amphetamines
Phentermines
Cathinones
Phenylisobutylamines
(and further-extended)
Catecholamines
(and close relatives)
Cyclized
phenethylamines
Phenylalkylpyrrolidines
2-Benzylpiperidines
(phenidates)
Phenylmorpholines
(phenmetrazines)
Phenyloxazolamines
(aminorexes)
Isoquinolines and
tetrahydroisoquinolines
2-Aminoindanes
2-Aminotetralins
Others / unsorted
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=Cericlamine&oldid=1268850823"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp